(HIK) Hikma Pharmaceuticals
Summary
Trade long or short on this share now through an Interactive Investor Spread Bet or CFD
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Headline | Source | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 02-02-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 6895W Hikma Pharmaceuticals Plc 02 February 2012
Notification of Major Interests in Shares
LONDON, 2 February 2012 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:
- ENDS - About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders of $99 million (2009 $78 million). This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 01-02-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 6086W Hikma Pharmaceuticals Plc 01 February 2012
Michael Ashton Appointment to PuriCore plc
London, 1 February 2012 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) makes this announcement in accordance with Listing Rule LR 9.6.14, which requires Hikma to notify the market when directors of Hikma become directors of other publicly traded companies.
Mr. Michael Ashton, an independent non-executive director of Hikma, has been appointed as an independent non-executive director of PuriCore plc (LSE: PURI) with effect from 1 February 2012.
"PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology offers a safe and non-hazardous approach to disinfection and sanitisation." Source: PuriCore plc
- ENDS - Enquiries:
Hikma Pharmaceuticals PLC Henry Knowles, Company Secretary +44 (0)20 7399 2760
Notes to Editors
About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 17-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 6897V Hikma Pharmaceuticals Plc 17 January 2012
PRESS RELEASE
Hikma completes mandatory tender offer, raising its stake in Promopharm to 94.1% London, 17 January 2012 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) ("Hikma"), the fast growing multinational pharmaceutical group, today announces that it has increased its stake in Société de Promotion Pharmaceutique du Maghreb S.A. (Casablanca: PRO) ("Promopharm") from 63.9% to 94.1%. Hikma acquired the additional 302,196 shares (representing 30.2% of Promopharm) for an aggregate consideration of $41.6 million (MAD 349.0 million). These shares were purchased in the open market and through a mandatory tender offer, which closed on 6 January 2012. The remaining 5.9% of Promopharm's issued share capital has been retained by existing shareholders and Promopharm will remain listed on the Casablanca Stock Exchange. ----- ENDS -----
Enquiries Hikma Pharmaceuticals PLC Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760/07776 477 050
FTI Consulting +44 (0)20 7831 3113 Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole
Acquisition of Promopharm On 3 October 2011, Hikma announced that it had acquired 63.9% of Promopharm from a consortium of shareholders comprising existing management, institutions and related parties for an aggregate consideration of $111.2 million (MAD 912.8 million).
About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2010, Hikma achieved revenues of $731 million and profit attributable to shareholders of $99 million.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 13-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 5260V Hikma Pharmaceuticals Plc 13 January 2012 Annex DTR3 Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons All relevant boxes should be completed in block capital letters
Notes: This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4 (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Result Pages: 1 | ||||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| 15-12-11 | ||||
|
|
||||
|
|
||||
|
......these 3 stocks are well worth looking into and are potentially multi-multi baggers...if all goes to plan of course!
****ANGEL BIO-TECHNOLOGY-ABH, stem cell research..this little company is a MUST HAVE in every portfolio, sp on the floor and high risk/reward scenario! http://www.proactiveinvestors.co.uk/companies/news/34438/angel-biotechnology-up-185-per-cent-after-russian-jv-deal-announced-34438.html {Stewart White-new appointment!} http://shares.telegraph.co.uk/news/article.php?id=4270251&epic=ABH http://edinburghsciencetriangle.mobi/site/news.asp?a=Life%20Sciences&id=N-10511&imz_ed=www.edinburghsciencetriangle.net&imz_s=fk5clkquuondqgo0k33942bbf0 Presentation-video, a must watch! http://www.youtube.com/watch?v=7TxCt29pLVk http://www.proactiveinvestors.co.uk/companies/news/6044/angel-biotechnology-to-manufacture-stem-cells-for-reneuron-phase-i-clinical-trial-6044.html Scientist, closer to blood cancer cures! http://www.crm.ed.ac.uk/news/press-releases Daily Mail(must read) http://www.dailymail.co.uk/health/article-2071076/Stem-cell-therapy-poised-shake-medicine-dozens-clinical-trials-early-success.html News results for ABH and share price! http://www.stockmarketwire.com/company-news/?epic=ABH Research-articles,etc http://www.iii.co.uk/investment/detail/?display=discussion&code=cotn%3AABH.L&thread=9001246&it=le&action=list ****VALiRX-VAL (HIGH RISK-but with great potential) current sp 0.52p, half a penny! VAL-launches self testing kit..... http://www.proactiveinvestors.co.uk/companies/news/36062/valirx-launches-self-testing-products-in-east-midlands-region-36062.html News-RNS' for ValiRx-VAL and share price! http://www.stockmarketwire.com/company-news/?epic=VAL http://www.iii.co.uk/investment/detail?code=cotn:VAL.L&display=news&it=le ***SYNAIRGEN-SNG, research bio-asthma/COPD, http://www.synairgen.com/ http://uk.finance.yahoo.com/news/Synairgen-plc-Positive-Viral-afxcnf-3155773929.html?x=0 (RHPS - tip) http://www.synairgen.com/programme_IFNB.asp aimZine: http://www.aimzine.co.uk/aimzine/0511/0511_A7/0511_A7.htm News results for SNG and share price! http://www.stockmarketwire.com/company-news/?epic=SNG Proactive-Investors http://www.proactiveinvestors.co.uk/companies/news/36139/-synairgen-shares-up-on-positive-results-for-ifn-beta-in-viral-pneumonia-study-36139.html |
||||
| 04-11-11 | ||||
|
|
||||
|
|
||||
|
Hikma Pharmaceuticals climbs on solid growth
By Darshini Shah | Fri, 04/11/2011 - 11:18 Hikma Pharmaceuticals (HIK) has trimmed gross margin expectations for the full year to 46%, while maintaining its top-line and net profit guidance. In its third-quarter trading update released on Friday, the company confirmed that the US generics division, which makes up about 18% of total sales, remained the weak link as industry-wide pricing pressure was offsetting solid volume growth. Revenue guidance for the division was cut from $160 million (c£100 million) to $155 million, with a "low double-digit" versus "low teens" pre-tax profit margin. Revenue growth in the branded division was 9% for the nine months, from 3% in the first half. The acceleration in growth was due to the disruption in the Middle East and North Africa (MENA) region. The company confirmed that full-year growth would be about 7% due to tough comparables in the fourth quarter. Injectables saw "strong" double-digit sales with a "significant improvement" in operating margin. On the recently acquired Multi-source Injectables (MSI) business, Hikma guided to full-year revenues of between $100 million and $105 million, with the business breaking even in the second half of 2011. "The excellent performance of our global injectables business, our rapid progress in integrating the MSI business in the US and the resilience of our operations in MENA demonstrate the strength of our diversified business model," commented chief executive Said Darwazah. Preliminary results for the 12 months to 31 December will be announced on 14 March. |
||||
| 27-10-11 | ||||
|
|
||||
|
|
||||
|
Market Report: Ratings boost gives drugs firm Hikma a healthy glow
Toby Green Thursday, 27 October 2011 http://www.independent.co.uk/news/business/sharewatch/market-report-ratings-boost-gives-drugs-firm-hikma-a-healthy-glow-2376396.html Investors were told to stop worrying about the Arab Spring and pile into Hikma yesterday. The Jordan-based generic drugs maker was driven up 35p to 665p after Morgan Stanley argued that despite recent conflicts, the pharmaceuticals market in North Africa and the Middle East remained on course to soar. Upgrading his rating to "overweight", the broker's analyst Peter Verdult said that the region – which currently provides almost 60 per cent of Hikma's revenues – contained "some of the fastest-growing pharma markets with relatively high entry barriers". The company has already said that despite some disruption to its operations, it expects to benefit from the fallout of the Arab Spring, claiming governments will be forced to listen more closely to their citizens and subsequently increase spending on healthcare. Hikma's quest to expand in the region took a further step earlier in the month after it agreed to buy more than 60 per cent of Morocco's Promopharm for $111.2m (£69.8m). Mr Verdult said the acquisition "reinforces the growth story" and estimated that this year it would contribute $55m worth of sales. |
||||
| 24-08-11 | ||||
|
|
||||
|
|
||||
|
And at 615p, this share is even better value. MENA loves its medicines and generally has the (oil) money to pay for them; plus a manufacturing base in India for the generics will support the value even more. The share deserves a higher rating.
|
||||
|
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
Markets: FTSE 100 in the black as Bank announces more QEEditor's Pick:
Bank announces £50bn quantitative easing packageEditor's Pick:
View from the top: Tangiers Petroleum interviewEditor's Pick:
Mixed outlook for trio of mining giantsEditor's Pick:
Barryroe update boosts Providence and LansdowneEditor's Pick:
Vodafone reveals weaker-than-expected performanceEditor's Pick:
Nighthawk announces new Jolly Ranch investmentEditor's Pick:
Glenstrata's just a silly word. Stick to big dividendsEditor's Pick:
Bulls should head for ChinaEditor's Pick:
George Godber’s AIM stock picks
Share
